Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report

Immune-related adverse events (irAEs) pose a significant challenge for the widespread adoption of immuno-oncology therapies, but their symptoms can vary widely. In particular, the relationship between irAEs and pleural effusion (PE) in patients with advanced non-small cell lung cancer (NSCLC) remain...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Xiao-Hong, Shen, Pan-Xiao, Wu, Jian-Hui, Qiu, Gui-Huan, Lin, Xin-Qing, Xie, Zhan-Hong, Qin, Yin-Yin, Zheng, Bin, Liu, Ming, Zhou, Cheng-Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Immunotherapy - Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399467/
https://www.ncbi.nlm.nih.gov/pubmed/37529904
http://dx.doi.org/10.1080/21645515.2023.2240689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399467/
https://www.ncbi.nlm.nih.gov/pubmed/37529904
http://dx.doi.org/10.1080/21645515.2023.2240689

Ejemplares similares